Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Unicycive Therapeutics (NASDAQ:UNCY), a clinical-stage biotechnology company focused on kidney disease therapies, has successfully regained compliance with Nasdaq's minimum bid price requirement. The compliance was achieved following a 1:10 reverse stock split that became effective on June 20, 2025.
The company received official confirmation from Nasdaq's Listing Qualifications Department on July 7, 2025, stating that UNCY's common stock has maintained an average closing share price of at least $1.00. This resolves the previous listing compliance issue, and Nasdaq has officially closed the matter.
Unicycive Therapeutics (NASDAQ:UNCY), una società biotecnologica in fase clinica specializzata in terapie per le malattie renali, ha riconquistato con successo la conformità al requisito minimo di prezzo per azione di Nasdaq. La conformità è stata raggiunta a seguito di uno split inverso azionario 1:10 diventato effettivo il 20 giugno 2025.
La società ha ricevuto la conferma ufficiale dal Dipartimento di Qualificazione delle Quotazioni di Nasdaq il 7 luglio 2025, che ha attestato come il prezzo medio di chiusura delle azioni ordinarie di UNCY sia rimasto almeno a $1,00. Questo ha risolto il precedente problema di conformità alla quotazione, e Nasdaq ha ufficialmente chiuso la questione.
Unicycive Therapeutics (NASDAQ:UNCY), una empresa biotecnológica en etapa clínica centrada en terapias para enfermedades renales, ha recuperado con éxito el cumplimiento del requisito mínimo de precio por acción de Nasdaq. El cumplimiento se logró tras una consolidación inversa de acciones 1:10 que entró en vigor el 20 de junio de 2025.
La compañía recibió la confirmación oficial del Departamento de Calificaciones de Listado de Nasdaq el 7 de julio de 2025, indicando que el precio promedio de cierre de las acciones ordinarias de UNCY se mantuvo en al menos $1.00. Esto resuelve el problema previo de cumplimiento con la cotización, y Nasdaq ha cerrado oficialmente el asunto.
Unicycive Therapeutics (NASDAQ:UNCY)는 신장 질환 치료에 중점을 둔 임상 단계 생명공학 회사로, 나스닥의 최소 입찰가 요건을 성공적으로 충족하였습니다. 이 준수는 2025년 6월 20일에 발효된 1:10 역주식 분할 이후 이루어졌습니다.
회사는 2025년 7월 7일 나스닥 상장 자격 부서로부터 UNCY 보통주의 평균 종가가 최소 $1.00 이상임을 공식 확인받았습니다. 이로써 이전의 상장 준수 문제는 해결되었으며, 나스닥은 공식적으로 해당 사안을 종결했습니다.
Unicycive Therapeutics (NASDAQ:UNCY), une société biotechnologique en phase clinique spécialisée dans les thérapies pour les maladies rénales, a réussi à se conformer à l'exigence minimale du prix de l'action de Nasdaq. Cette conformité a été obtenue suite à une division inverse d'actions 1:10 entrée en vigueur le 20 juin 2025.
L'entreprise a reçu la confirmation officielle du Département des qualifications de cotation de Nasdaq le 7 juillet 2025, indiquant que le cours moyen de clôture des actions ordinaires de UNCY est resté au moins à 1,00 $. Cela résout le problème de conformité précédent, et Nasdaq a officiellement clos le dossier.
Unicycive Therapeutics (NASDAQ:UNCY), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf Nierenerkrankungen, hat erfolgreich die Einhaltung der Mindestgebotspreisanforderung der Nasdaq wiedererlangt. Die Einhaltung wurde durch eine 1:10 Reverse-Aktienzusammenlegung erreicht, die am 20. Juni 2025 wirksam wurde.
Das Unternehmen erhielt am 7. Juli 2025 eine offizielle Bestätigung von der Listing Qualifications-Abteilung der Nasdaq, dass der durchschnittliche Schlusskurs der Stammaktien von UNCY mindestens 1,00 $ beträgt. Dies löst das vorherige Problem der Börsenzulassung, und Nasdaq hat die Angelegenheit offiziell abgeschlossen.
- Successfully regained Nasdaq listing compliance
- Maintained required $1.00 minimum share price post reverse split
- Implementation of 1:10 reverse stock split indicates previous trading price weakness
--Nasdaq compliance follows reverse stock split previously announced on June 17, 2025
LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company’s Current Report on Form 8-K filed on July 8, 2025.
On July 7, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company’s common stock has maintained an average closing share price of at least
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com
FAQ
What was the ratio of Unicycive Therapeutics (UNCY) reverse stock split in 2025?
When did UNCY regain Nasdaq compliance?
What is Nasdaq's minimum bid price requirement that UNCY had to meet?
What is Unicycive Therapeutics' main business focus?
